CYNATA
Cynata Therapeutics Limited is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerusโข, using discoveries made at the University of Wisconsin-Madison (UWM). UWM is a world-renowned leader in stem cell research, in particular for the work by Professor James Thomson's group, which included the first successful isolation of human embryonic stem cells in 1998, and the derivation of induced pluripotent stem cells (iPSCs) fro... m human adult cells in 2007. Professor Igor Slukvin, a co-founder of Cynata, was also a member of the team that conducted UWM's pioneering iPSC research. Cynata's Cymerusโข platform stem cell technology is based upon extremely important and versatile stem cells known as mesenchymoangioblasts (MCAs). MCAs are a precursor of mesenchymal stem (or stromal) cells (MSCs) which are at the forefront of a new generation of treatments being investigated for such devastating diseases as osteoarthritis, Crohnโs disease and heart disease. Cynataโs proprietary technology utilizes iPSCs originating from an adult donor as the starting material for generating MCAs and in turn for manufacturing the MSC therapeutic product. Cynata will use the proprietary Cymerusโข technology to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. This opens up a wide range of therapeutic and manufacturing possibilities for the Company. The Cymerusโข technology has several characteristics which makes it ideal for the development of cell-based therapeutics. Most critically, the Cymerusโข manufacturing process ensures that cells for therapeutic use can be produced in virtually limitless quantities. This means that Cynata will not have to constantly seek out fresh stem cell donors to fuel its manufacturing demands. This has the potential to create a new standard in the emergent arena of regenerative medicine and stem cell therapeutics and provides Cynata with both a unique differentiator and an important competitive position.
CYNATA
Industry:
Biotechnology Health Care Life Science
Founded:
2003-01-01
Address:
Armadale, Victoria, Australia
Country:
Australia
Website Url:
http://www.cynata.com
Total Employee:
1+
Status:
Active
Contact:
+610893242099
Email Addresses:
[email protected]
Total Funding:
12.84 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Tag Manager Content Delivery Network Google Universal Analytics Apache
Similar Organizations
Amwise Diagnostic
Amwise Diagnostic is a leader in precision medicine technology for cancer.
Inscripta
Inscripta is a life science technology company that develops digital genome engineering solutions.
LYFE Capital
LYFE Capital is a life science investment firm.
Themis Bioscience
Themis Bioscience is a start-up biotechnology company.
Voyager Therapeutics
Voyager Therapeutics is a gene therapy company developing treatments for fatal and debilitating diseases of the central nervous system
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Fidelity International
Fidelity International investment in Post-IPO Equity - Cynata
Fujifilm
Fujifilm investment in Post-IPO Equity - Cynata
Official Site Inspections
http://www.cynata.com Semrush global rank: 8.73 M Semrush visits lastest month: 261
- Host name: ec2-3-104-15-148.ap-southeast-2.compute.amazonaws.com
- IP address: 3.104.15.148
- Location: Sydney Australia
- Latitude: -33.8591
- Longitude: 151.2002
- Timezone: Australia/Sydney
- Postal: 2000